Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16179964 | 0.68 | CA1 (0.32) | CA1CA2CA4 | |
| SCHEMBL16625524 | 0.68 | PDE4A (0.34) | POLBCA1CA2CA4 | |
| Ethane SCHEMBL28079163 | 0.63 | KMT2A (0.39) | KDM4EPOLBL3MBTL1CA1CA2 | |
| SCHEMBL59379 | 0.62 | KDM4E (0.37) | KDM4EPOLBL3MBTL1CA1CA2 | |
| SCHEMBL15858588 | 0.61 | ALDH1A1 (0.41) | — | |
| SCHEMBL7642946 | 0.61 | CA1 (0.35) | KDM4EPOLBL3MBTL1CA1CA2 | |
| SCHEMBL28614043 | 0.60 | KDM4E (0.36) | KDM4EPOLBL3MBTL1CA1CA2 | |
| SCHEMBL11739358 | 0.60 | KDM4E (0.36) | KDM4EPOLBL3MBTL1CA1CA2 | |
| SCHEMBL27714283 | 0.60 | KDM4E (0.37) | KDM4EPOLBL3MBTL1 | |
| SCHEMBL7635786 | 0.59 | KMT2A (0.38) | KDM4EPOLBL3MBTL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090175812-A1 | Novel Skin Lightening Agents, Compositions and Methods | CONOPCO, INC., D/B/A UNILEVER (US) | 2009-07-09 | — | — | US | disclosed |
| US-7524485-B2 | Skin lightening agents, compositions and methods | UNILEVER HOME & PERSONAL CARE, USA, DIVISION OF CONOPCO, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20050186231-A1 | Stabilization with substituted ureas against color degradation of personal care products | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2005-08-25 | — | — | US | disclosed |
| US-6875425-B2 | Skin lightening agents, compositions and methods | UNILEVER HOME & PERSONAL CARE USA (US) | 2005-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175812-A1 | Novel Skin Lightening Agents, Compositions and Methods | C1R, CBR1, OXER1 | KDM4E 4727/4885POLB 1536/4885L3MBTL1 817/4885 |
| US-20050186231-A1 | Stabilization with substituted ureas against color degradation of personal care products | CUTA, PUF60, USP10 | KDM4E 2270/4885POLB 1860/4885L3MBTL1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.